Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropeg-interferon in Newly Diagnosed JAK2-Mutant Polycythemia Vera
NCT07886801Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2026
- Primary completion
- Oct 2029
- Countries
- 1
01
Overview
A Phase 2 trial of ropeginterferon alfa-2b in polycythemia vera (PV), sponsored by Memorial Sloan Kettering Cancer Center. Started Oct 2026; status: recruiting.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT07886801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07886801.